Skip to content

Supplier News

Coalition formed to safeguard access to OTC pain relievers

Coalition formed to safeguard access to OTC pain relievers

A group of drug- and health-related companies and organizations have formed the Protecting Access to Pain Relief Coalition (PAPR), which seeks to preserve Americans’ access to and choice of safe, effective pain relief best-suited for their condition.

GPhA tabs Davis as new CEO

GPhA tabs Davis as new CEO

Chester “Chip” Davis has been named president and chief executive officer of the Generic Pharmaceutical Association (GPhA), taking over from Ralph Neas, who is stepping down.

Qore-24 hits shelves at Walgreens stores

Qore-24 hits shelves at Walgreens stores

Qore-24, an antimicrobial hand purifier that kills germs for up to 24 hours, has landed retail distribution at Walgreens. Qore Systems, the maker of Qore-24, said Tuesday that the product began rolling out to 3,700 Walgreens stores nationwide earlier this month.

Yes To tabs Jackel as CEO

Yes To tabs Jackel as CEO

Ingrid Jackel is joining natural beauty care manufacturer Yes To Inc. as chief executive officer. Yes To said Monday that Jackel comes to Yes To from Physicians Formula, where she held a variety of positions, including CEO, president and chairwoman.

Galderma set to launch Epiduo Forte Gel

Galderma set to launch Epiduo Forte Gel

Galderma Laboratories has received Food and Drug Administration approval for antibiotic-free Epiduo Forte Gel (adapalene and benzoyl peroxide 0.3%/2.5%), a once-daily topical acne treatment. Galderma said Thursday Epiduo Forte Gel is the first combination of 0.3%/2.

Marketing veteran joins Hershey as CMO

Marketing veteran joins Hershey as CMO

Hershey Co. has hired Capital One Financial Corp. executive Peter Horst as senior vice president and chief marketing officer. Hershey said Thursday that Horst will start at the company on July 27. At Capital One Financial, Horst most recently was senior vice president of brand marketing.

Novartis set to release Entresto heart failure drug

Novartis set to release Entresto heart failure drug

Novartis has received Food and Drug Administration approval for Entresto (sacubitril/valsartan) tablets, a medication for heart failure with reduced injection fraction. An angiotensin receptor neprilysin inhibitor (ARNI), Entresto reduces the strain on a failing heart.